That would definately be interesting Hesk, and as you say not to...

That would definately be interesting Hesk, and as you say not to be ruled out. It has been some time since the blockbuster trials we did with omomyc, but that being said it is a little strange that we do still keep using and reffering to omomyc as a company.

I was of tge understanding that onomyc was owned by Dr Soucek, but if we could create a similar compound with a slightly different structure we would have our own version? The current statements from the company seem a bit contradictory- we could be partnerung with Dr Soucek because we keep wirking with omomyc. At the same time if that were the case why comtinue searching for our own inhibolitor for what will be a year soon? A year that we could really do without funding if we could take omomyc directly to the trials we are working towards?

Each cr covers 2-3 years so if we are working with Dr Soucek we are wasting a lot of money, unless both parties agree we could find something even more effective?

I wonder how different our proprietry inhibitor needs to be so as not to impinge on omomyc if we are not collaborating??